ArticleThe world journal of men's health2020
Diagnostic Performance of
Article in The world journal of men's health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Current insights on PSMA PET/CT in intermediate-risk prostate cancer: a literature review.Annals of nuclear medicine · 2025Pooled it
- Head-to-Head Comparison ofFrontiers in oncology · 2021Pooled it
- PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Pooled it
- The Role ofFrontiers in oncology · 2020Pooled it
- Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas.Current radiopharmaceuticals · 2020Pooled it
- [European journal of nuclear medicine and molecular imaging · 2021Trial
- Detection of prostate cancer withWorld journal of urology · 2021Trial
- Pelvic lymph-node staging withEuropean journal of nuclear medicine and molecular imaging · 2021Trial
- Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era.The Prostate · 2026Review
- Head-to-head comparison ofEJNMMI research · 2026Article
- Diagnostic performance of conventional MRI using T1W and T2W for primary lymph node staging in intermediate- and high-risk prostate cancer patients prior to pelvic lymph node dissection.Abdominal radiology (New York) · 2026Observational
- Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI-Driven Biomarkers.Cancers · 2025Review
- Impact ofDiagnostics (Basel, Switzerland) · 2025Article
- Fluorescence-guided lymphadenectomy in robot-assisted radical prostatectomy: the role of interventional radiology.Frontiers in radiology · 2025Article
- Diagnostic value ofCancer biology & therapy · 2024Article
- Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment.Cancers · 2024Review
- Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer.EJNMMI radiopharmacy and chemistry · 2024Review
- Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.The British journal of radiology · 2024Review
- Predictors of Metastasis in 68GA-Prostate Specific Membrane Antigen Pet-CT in the Primary Staging of Prostate Cancer.Journal of clinical medicine · 2024Article
- Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate- to high-risk prostate cancer.The British journal of radiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo compare the diagnostic efficiency of MATERIALS AND
methodsA broad search of scientific databases including PubMed, EMBASE, Web of Science, Cochrane Database, and Chinese Biomedicine Literature Database (updated prior to November 1st, 2018) was conducted systematically by two reviewers. In this paper, we evaluated the methodological quality of each included article independently and performed a systematic review and meta-analysis to reveal the summary of the diagnostic performance of
resultsThirteen eligible articles comprising 1,597 patients were included. For LNMs detection, the pooled sensitivity and specificity of
conclusionsIn intermediate- or high-risk pre-treatment prostate cancer,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.